NAUTILUS BIOTECHNOLGY INC (NAUT)
Health Care · Life Sciences Tools & Services · NASDAQ
Developing a high-throughput, single-molecule proteomics platform designed to unlock the complexity of the human proteome.
What NAUTILUS BIOTECHNOLGY INC does
Nautilus Biotechnology is a development-stage life sciences company building an end-to-end proteomics platform designed to quantify and characterize the human proteome at scale. The company’s primary product under development, the Nautilus Voyager, utilizes a proprietary method called Iterative Mapping to measure single, intact protein molecules using nanofabricated arrays, affinity reagents, advanced optics, and machine learning. Nautilus is currently focused on research and development and has not yet generated material commercial revenue.
Themes: proteomics, biotechnology R&D, single-molecule analysis, next-generation sequencing/analysis technologies
Fundamentals
- Price$1.82 as of 2026-10-08 close
- Market cap$232M as of 2026-07-24 (share count; price 2026-10-08)
- 1-year return+101.8% 2025-10-08 close $0.902 → 2026-10-08 close $1.82
- P/En/a negative earnings
- ROE-37.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.64 as of 2026-09-03
- Last reported earnings2026-07-28 SEC EDGAR Form 8-K (Item 2.02)
How NAUT compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NAUTILUS BIOTECHNOLGY INC looks technically
NAUTILUS BIOTECHNOLGY INC (NAUT) is trading 11.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 53 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 5 trading days ago. It is 57.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 11.2% below its 200-day average, the long-term trend line — a long-term downtrend | -11.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.07 | $1.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.05 | $2.05 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 0.88. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 53 trading days ago — a "death cross", a bearish long-term signal | 53 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with buyers in control | 41.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 68, neither overbought (above 70) nor oversold (below 30) | 67.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($0.9 to $2.48) — its "stochastic" reading is 58 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 58.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 40 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.31 | $4.31 |
|---|---|---|
| From the 52-week high | it is 57.8% below its 52-week high (its highest price of the past year) | -57.8% |
| Above the 52-week low | it is 122.0% above its 52-week low (its lowest price of the past year) | +122.0% |
| Below the 52-week high | it is 57.8% below its highest point of the past year | 57.8% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $11.66 (set on 2021-08-05) | $11.66 |
| Given back of the 52-week move | over the past year its closes ranged ($0.835 to $3.95), and it has given back well over two thirds of its rise from last year’s low — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.93 to $2.02. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 68.4% |
| From the all-time high | it is 84.4% below its all-time high | -84.4% |
| Nearest price level | it is trading 2.4% below a resistance level at $1.86 — a price it turned at five times since 2024-12-05, most recently on 2026-01-30. Since 2024-10-08 it has 8 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.4% |
| All-time low | its lowest closing price on record is $0.62 (set on 2025-09-04) | $0.62 |
| Above the all-time low | it is 193.5% above its all-time low | +193.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2347 between its high and its low — about 12.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2347 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.49 and $2.05 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.49 – $1.27 – $2.05 |
| Typical daily range (% of price) | its price moves about 12.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 12.9% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (11.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.44× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 4.2% since the prior reading | -4.2% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 2.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +2.0% |
|---|---|---|
| Open gap | it gapped 5.1% above the previous close 4 sessions ago and has not traded back through the level it left behind at 1.57 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.1% |
| Gap filled | a 2.0% gap up opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 95.1 percentage points (the stock gained 96.1% while the market gained 1.0%) | +95.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.6 percentage points (the stock gained 2.2% while the market gained 3.8%) | -1.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 63.1 percentage points (the stock lost 45.7% while the market gained 17.5%) | -63.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 86.8 percentage points (the stock gained 101.8% while the market gained 15.0%) | +86.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 31.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +10.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.75 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +4.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% above the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $1.51 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | +20.4% |
Price levels it has turned at before
NAUT last closed at $1.82 on 2026-10-08. Since 2024-10-08 it has turned at 8 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.86 | Resistance | 2.4% above the last close | turned there five times · 2024-12-05 to 2026-01-30 |
| $1.76 | Support | 3.1% below the last close | turned there three times · 2025-02-14 to 2026-01-16 |
| $2.06 | Resistance | 13.0% above the last close | turned there twice · 2025-12-29 to 2026-07-10 |
| $1.57 | Support | 13.9% below the last close | turned there three times · 2025-02-12 to 2026-07-17 |
| $2.29 | Resistance | 26.0% above the last close | turned there three times · 2026-01-08 to 2026-05-21 |
| $0.8452 | Support | 53.6% below the last close | turned there three times · 2025-07-03 to 2026-08-18 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $0.88.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 13 trading days, since 2026-09-22.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · Analyst price target recently CUT · lagging the market · Left an unfilled gap (5%+ in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$3.83 range $3.50 – $4.00; median $4.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["The company has not generated material revenue and has a history of losses, with no assurance of achieving future profitability.","The successful commercialization of the Nautilus Voyager platform is subject to significant technical, manufacturing, and supply chain risks, particularly regarding complex multi-affinity reagents and antibodies."]
What changed in the latest 10-Q
AI-assisted comparison of NAUT's 10-Q filed 2026-04-28 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references audited financial statements for year ended December 31, 2025 and Form 10-K filed February 26, 2026 (vs. December 31, 2024 and February 27, 2025 in older filing)
- Newer filing specifies 'Iterative Mapping' as the analysis method name in Overview section
- Newer filing introduces 'Iterative Mapping' technology branding throughout Overview (not present in older filing)
- Newer filing states company made first sales hire during three months ended March 31, 2026
- Newer filing describes 'land-and-expand strategy' with targeted proteoform analysis and broadscale proteomics applications
- Newer filing references 'Early Access Program' with service model for sample analysis in company facility shared via cloud platform
- Newer filing specifies Iterative Mapping Early Access Program launch 'starting with target specific service offerings in January 2026'
- Newer filing references commercial launch 'in late 2026 by opening the Nautilus Voyager platform for pre-orders, with instrument installation'
- Removed:
- Older filing's statement 'Our vision is to integrate our breakthrough innovations in computer science, engineering, and biochemistry...' removed in newer filing
- Older filing's reference to 'a prototype of a proteome analysis system' removed in newer filing
- Older filing's three-phase commercialization plan description removed from newer filing
- Older filing's statement 'Given our stage of development, we have not yet established a commercial organization or distribution capabilities' removed in newer filing
- Older filing's description of collaboration phase activities removed in newer filing
- Older filing's reference to 'over 300 complex reagents' changed in newer filing
- Reworded:
- Newer filing: 'focused on creating a platform technology to quantify and unlock the complexity' vs. older: 'creating a platform technology for quantifying and unlocking the complexity'
- Newer filing describes company 'were founded to address longstanding challenges in proteomics through the development of a new analysis method, Iterative Mapping' vs. older filing's broader mission statement about democratizing access and revolutionary precision medicine
- Newer filing: 'Nautilus Voyager TM platform is designed to implement the Iterative Mapping method' (explicit naming of platform)
- Newer filing: 'approximately 300 unique multi-affinity reagents' vs. older: 'over 300 complex reagents'
- Newer filing: 'we made our first sales hire as an initial step toward building an internal sales infrastructure' vs. older: 'we have not yet established a commercial organization or distribution capabilities'
- Newer filing: references 'Early Access Program' specifically vs. older: 'early access limited release' and 'second phase'
- Newer filing: 'announced the launch of our Iterative Mapping Early Access Program starting with target specific service offerings in January 2026' vs. older: 'expect to launch early access to our platform starting with target specific service offerings in the first half of 2026'
- Notes:
- Older filing text appears truncated at end ('We expect this second phase to lead into the third phase of launch of our proteome analysis platform in late 2026 and s'), limiting complete comparison of final sections
- Newer filing text also appears truncated ('with instrument installation' incomplete sentence), preventing full assessment of closing statements
- Page number changed from 19 to 17 between filings, but this reflects pagination differences rather than content changes
Risk Factors
- Added:
- Added bullet point in summary: 'We may never achieve profitability' (filed 2026-04-28)
- Added bullet point in summary: 'which may not be available to us on favorable terms or at all' regarding capital raising (filed 2026-04-28)
- Added bullet point in summary: 'and how we transmit analytical data to our customers' regarding data regulations (filed 2026-04-28)
- Added new bullet point: 'Our operations and financial results could be adversely impacted by global and national events, such as global geopolitical conflicts, including war, trade embargoes, tariff policies and boycotts, changing interest rates, volatility in the global financial markets and general economic downturns' (filed 2026-04-28)
- Removed:
- Removed from older bullet point: reference to 'COVID-19 pandemic' and 'conflicts in Eastern Europe and the Middle East, increased tariffs, trade disputes' (filed 2025-10-28)
- Removed from older capital raising bullet point: no specific language about terms or availability conditions (filed 2025-10-28)
- Removed reference to anticipated 'cost savings associated with our workforce reductions' from detailed risk discussion (filed 2025-10-28)
- Reworded:
- Changed platform name from 'Nautilus platform' to 'Nautilus Voyager™ platform' throughout (filed 2026-04-28)
- Changed bullet point from 'We are dependent upon third parties for certain aspects of the development and commercialization of the Nautilus platform' to reference 'Nautilus Voyager platform' (filed 2026-04-28)
- Changed bullet point from 'We may not be able to launch our Nautilus platform successfully' to 'We may not be able to launch our Nautilus Voyager platform successfully' (filed 2026-04-28)
- Updated financial figures in detailed risk discussion: net losses changed from '$13.6 million and $45.2 million during the three and nine months ended September 30, 2025' to '$14.7 million and $16.6 million during the three months ended March 31, 2026 and 2025, respectively' (filed 2026-04-28)
- Updated accumulated deficit from '$318.2 million as of September 30, 2025' to '$346.7 million as of March 31, 2026' (filed 2026-04-28)
- Changed description of global events from specific examples to broader categories including 'war, trade embargoes, tariff policies and boycotts, changing interest rates, volatility in the global financial markets' (filed 2026-04-28)
- Notes:
- The newer filing text appears truncated at the end of the detailed risk section and may not contain the complete discussion.
- The older filing text also appears truncated and may not contain complete content.
- Financial figures and dates reflect different reporting periods (March 31, 2026 vs. September 30, 2025), making direct comparisons reflect both period differences and company performance changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 2 sells ($12M) — 1 selling insider
Most recent open-market transaction: 2026-06-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NAUT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NAUT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,810,415
- Reported value $14,605,476
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NAUT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NAUT had 4,082,014 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NAUT had 3.21% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.24 days to cover at the same settlement.
- Reported short interest (shares) 4,082,014
- Short interest (% of shares outstanding) 3.21%
- Prior settlement (shares) 3,814,029
- Reported change 7.03%
- Days to cover (reported) 3.24
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Seer (SEER)
- Olink Holding (OLK)
- Quanterix (QTRX)
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Agilent Technologies (A)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NAUT vs…
NAUT ranks in…
Frequently asked questions
What does NAUTILUS BIOTECHNOLGY INC (NAUT) do?
Nautilus Biotechnology is a development-stage life sciences company building an end-to-end proteomics platform designed to quantify and characterize the human proteome at scale. The company’s primary product under development, the Nautilus Voyager, utilizes a proprietary method called Iterative Mapping to measure single, intact protein molecules using nanofabricated arrays, affinity reagents, advanced optics, and machine learning.
What sector is NAUTILUS BIOTECHNOLGY INC (NAUT) in?
NAUTILUS BIOTECHNOLGY INC (NAUT) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NASDAQ.
Who are NAUTILUS BIOTECHNOLGY INC's (NAUT) competitors?
Notable peers of NAUTILUS BIOTECHNOLGY INC (NAUT) include Seer, Olink Holding, Quanterix, Thermo Fisher Scientific and Danaher. This peer set is informational only — not financial advice.
Is NAUTILUS BIOTECHNOLGY INC (NAUT) overbought or oversold right now?
NAUTILUS BIOTECHNOLGY INC (NAUT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 68, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NAUT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.